ERBB2 and breast carcinoma: In a proof-of-concept experiment, we assessed the cytotoxic capacity of WT and genetically modified CIK cells against the indicated ErbB2-overexpressing breast carcinoma cell line (MDA-MB-453, Table 1) by europium release assay (Figure 4B).